World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
90
Citations
30547
World Ranking
12184
National Ranking
6247

Overview

Mark J. Levis is a researcher affiliated with Johns Hopkins University in the United States. Their academic work primarily focuses on the field of medicine, with a significant emphasis on hematology. Other notable subfields of study associated with their research include genetics, molecular biology, public health, environmental and occupational health, and oncology.

The research contributions of Mark J. Levis cover a variety of topics related to leukemia and hematopoietic processes. Key topics in their work include:

  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Chronic Lymphocytic Leukemia Research
  • Acute Lymphoblastic Leukemia Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Hematopoietic Stem Cell Transplantation
  • Retinoids in leukemia and cellular processes

An overview of some recent significant papers by or involving Mark J. Levis includes:

  • Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial (2023, The Lancet)
  • Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia (2022, Journal of Clinical Oncology)
  • Updates on targeted therapies for acute myeloid leukaemia (2021, British Journal of Haematology)
  • Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia (2020, Bone Marrow Transplantation)
  • Gilteritinib: potent targeting of FLT3 mutations in AML (2020, Blood Advances)

Mark J. Levis has collaborated frequently with other researchers. The most common co-authors include:

  • Alexander E. Perl
  • Pau Montesinos
  • Amy E. DeZern
  • Richard F. Schlenk
  • Harry P. Erba

The scientist's work has often appeared in a range of scientific journals, with the highest number of publications in:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Haematologica
  • Blood Advances
  • Journal of Clinical Oncology

Best Publications

  • Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML

    Alexander E. Perl;Giovanni Martinelli;Jorge E. Cortes;Andreas Neubauer

  • Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

    Catherine C. Smith;Qi Wang;Chen Shan Chin;Sara Salerno

  • Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

    B. Douglas Smith;Mark Levis;Mark Levis;Miloslav Beran;Miloslav Beran;Francis Giles;Francis Giles

  • Targeting FLT3 mutations in AML: review of current knowledge and evidence.

    Naval Daver;Richard F. Schlenk;Nigel H. Russell;Mark J. Levis

  • AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

    Patrick P. Zarrinkar;Ruwanthi N. Gunawardane;Merryl D. Cramer;Michael F. Gardner

  • Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML

    Zhihong Zeng;Yue Xi Shi;Ismael J. Samudio;Rui Yu Wang

  • A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

    Mark Levis;Jeffrey Allebach;Kam-Fai Tse;Rui Zheng

  • FLT3: ITDoes matter in leukemia.

    M Levis;D Small

  • A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.

    Steven Knapper;Alan K Burnett;Timothy Littlewood;W Jonathan Kell

  • Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study

    Alexander E. Perl;Jessica K. Altman;Jorge Cortes;Catherine Smith

  • Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia

    Farhad Ravandi;Jorge E Cortes;Daniel Jones;Stefan H Faderl

  • Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

    Mark Levis;Farhad Ravandi;Eunice S. Wang;Maria R. Baer

  • Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status

    Jorge E. Cortes;Hagop Kantarjian;James M. Foran;Darejan Ghirdaladze

  • Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

    Jorge E. Cortes;Samer Khaled;Giovanni Martinelli;Alexander E. Perl

  • Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

    Farhad Ravandi;Mona Lisa Alattar;Michael R. Grunwald;Michelle A. Rudek

  • Palmitoylation is required for signaling functions and membrane attachment of Gq alpha and Gs alpha.

    P B Wedegaertner;D H Chu;P T Wilson;M J Levis

  • Risk-stratified outcomes of nonmyeloablative, HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide

    Shannon R. McCurdy;Jennifer A. Kanakry;Margaret M. Showel;Hua Ling Tsai

  • FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?

    Mark Levis

  • Midostaurin approved for FLT3-mutated AML

    Mark Levis

  • FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo

    Takashi Sato;Xiaochuan Yang;Steven Knapper;Paul Charles White

Frequent Co-Authors

Jorge E. Cortes
Jorge E. Cortes Augusta University
Donald Small
Donald Small Johns Hopkins University
B. Douglas Smith
B. Douglas Smith Johns Hopkins University
Judith E. Karp
Judith E. Karp Johns Hopkins University
Giovanni Martinelli
Giovanni Martinelli University of Bologna
Nigel H. Russell
Nigel H. Russell University of Nottingham
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Michael A. McDevitt
Michael A. McDevitt Johns Hopkins University
Richard J. Jones
Richard J. Jones Johns Hopkins University
Maria R. Baer
Maria R. Baer University of Maryland, Baltimore

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a traditional medical degree in the USA is only one pathway into healthcare. A growing number of students are seeking flexible and affordable options to enter healthcare or enhance their current careers through online education.

For pharmacy roles, students can explore online pharmacy schools that offer doctorate programs with remote coursework. Those interested in managing patient data may consider rhia certification programs online to qualify for careers in health information management.

Another in-demand option is medical coding certification online, allowing students to specialize in medical billing and coding without attending in-person classes. For nurses seeking to advance their practice, the cheapest online fnp program gives a pathway to becoming a family nurse practitioner at lower tuition rates.

These online programs can open doors to rewarding healthcare careers, providing flexibility for working students or those needing to balance other commitments.

Best Scientists Citing Mark J. Levis

Trending Scientists

Recently Published Articles